- Home
- FURY vs IMMX Comparison
FURY vs IMMX Comparison
Compare FURY & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- IMMX
- Stock Information
- Founded
- FURY 2008
- IMMX 2014
- Country
- FURY Canada
- IMMX United States
- Employees
- FURY N/A
- IMMX N/A
- Industry
- FURY Precious Metals
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- FURY Basic Materials
- IMMX Health Care
- Exchange
- FURY Nasdaq
- IMMX Nasdaq
- Market Cap
- FURY 59.6M
- IMMX 50.1M
- IPO Year
- FURY N/A
- IMMX 2021
- Fundamental
- Price
- FURY $0.39
- IMMX $1.87
- Analyst Decision
- FURY Strong Buy
- IMMX Strong Buy
- Analyst Count
- FURY 1
- IMMX 1
- Target Price
- FURY $1.20
- IMMX $7.00
- AVG Volume (30 Days)
- FURY 174.9K
- IMMX 43.0K
- Earning Date
- FURY 05-13-2025
- IMMX 05-08-2025
- Dividend Yield
- FURY N/A
- IMMX N/A
- EPS Growth
- FURY N/A
- IMMX N/A
- EPS
- FURY N/A
- IMMX N/A
- Revenue
- FURY N/A
- IMMX N/A
- Revenue This Year
- FURY N/A
- IMMX N/A
- Revenue Next Year
- FURY N/A
- IMMX N/A
- P/E Ratio
- FURY N/A
- IMMX N/A
- Revenue Growth
- FURY N/A
- IMMX N/A
- 52 Week Low
- FURY $0.35
- IMMX $1.26
- 52 Week High
- FURY $0.57
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- FURY 51.80
- IMMX 61.09
- Support Level
- FURY $0.36
- IMMX $1.61
- Resistance Level
- FURY $0.42
- IMMX $1.79
- Average True Range (ATR)
- FURY 0.03
- IMMX 0.15
- MACD
- FURY 0.00
- IMMX 0.04
- Stochastic Oscillator
- FURY 59.38
- IMMX 97.39
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.